Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital... More >>

Recent News

More >>
Cardiovascular Systems Announces Anticipated Revenue Impact from Hurricanes Harvey and Irma 09/18/17
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) today said that the impact of Hurricanes Harvey and Irma on procedure volumes in the greater Houston area and throughout Florida will reduce fiscal 2018 first-quarter revenues. “Our thoughts go out to our employees in Florida and Texas and others affected by Hurricanes Harvey and Irma,” said Scott Ward, CSI’s Chairman, President and Chief Executive Officer. “As recovery progresses, we will closely monitor conditions and the anticipated impact on our business. While these historic storms are affecting our near-term performance, they are not indicative of our long-term growth opportunity and continued market leadership position.” The potential revenue impact on CSI quarterly results is magnified due to the company’s small product portfolio and the location and timing of the storms. The Houston and Florida markets typically generate over 15% of CSI’s revenues. In addition, fiscal first quarter revenues are more heavily weighted in...
More >>
LIBERTY 360° Study 12-Month Sub-Analysis Reveals High Freedom from Major Amputation and Major Adverse Events (MAE) Using Cardiovascular Systems’ Diamondback 360® Peripheral Orbital Atherectomy System (OAS) 08/10/17
OAS utilization resulted in high Freedom from Major Amputation at one year across all Rutherford Classes (RC 2-3, 100%; RC 4-5, 95.8%; and RC 6, 91.2%) OAS prior to DCB therapy resulted in high Freedom from MAE at one year (95.2%) with no major amputations A new sub-analysis from the landmark LIBERTY 360° study, sponsored by Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), was presented today as part of a late-breaking presentation at the 2017 Amputation Prevention Symposium (AMP) in Chicago . The LIBERTY 360° study is designed to evaluate the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in patients with symptomatic lower extremity peripheral artery disease (PAD). Physicians were able to use any FDA-approved device, including CSI’s Diamondback 360® Peripheral OAS, which was the most frequently used atherectomy device in the study. The sub-analysis, highlighting 12-month Freedom from Major Adverse Events and Major Amputation, supports...
More >>

Upcoming Events

No items found